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Abdominal ultrasound fails to detect over one-fourth of hepatocellular car-
cinoma (HCC) at an early stage in patients with cirrhosis. Identifying
patients in whom ultrasound is of inadequate quality can inform interven-
tions to improve surveillance effectiveness.
Aim
To evaluate and identify predictors of ultrasound quality in patients with cirrhosis.
Methods
We performed a retrospective cohort study among patients who underwent
ultrasound examination for a cirrhosis-related indication between April 2015
and October 2015. Three fellowship-trained abdominal radiologists collec-
tively reviewed all ultrasound exams and categorised exam quality as defi-
nitely adequate, likely adequate, likely inadequate and definitely inadequate to
exclude liver lesions. We performed multivariable logistic regression to deter-
mine characteristics associated with inadequate ultrasound quality.
Results
Among 941 patients, 191 (20.3%) ultrasounds were inadequate for exclud-
ing HCC- 134 definitely inadequate and 57 likely inadequate. In multivari-
able analysis, inadequate quality was associated with male gender (OR 1.68,
95% CI 1.14–2.48), body mass index category (OR 1.67, 95% CI 1.45–1.93),
Child–Pugh B or C cirrhosis (OR 1.93, 95% CI 1.32–2.81), alcohol-related
cirrhosis (OR 2.11, 95% CI 1.33–3.37), NASH cirrhosis (OR 2.87, 95% CI
1.71–4.80), and in-patient status (OR 1.55, 95% CI 1.01–2.37). Ultrasounds
were inadequate in over one-third of patients with Child–Pugh C cirrhosis,
BMI >35, or NASH cirrhosis.
Conclusions
One in five ultrasounds in patients with cirrhosis are inadequate for exclu-
sion of HCC, which can contribute to surveillance failure. Alternative
surveillance modalities are needed in subgroups prone to inadequate ultra-
sounds including obese patients, those with Child Pugh B or C cirrhosis,
and those with alcohol- or NASH-related cirrhosis.
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INTRODUCTION
Ultrasound serves as the backbone of hepatocellular car-
cinoma (HCC) surveillance and is recommended every
6 months in patients with cirrhosis to improve early
tumour detection and overall survival.1, 2 Ultrasound can
be efficacious for early HCC detection, with a meta-ana-
lysis reporting a pooled sensitivity of 63% for detecting
HCC at an early stage.3 Several prospective cohort stud-
ies have demonstrated patients undergoing ultrasound-
based surveillance have earlier stages of disease as well as
improved survival, even after adjusting for lead time bias,
than those who had not undergone surveillance.4–6
A pillar of achieving this survival benefit in clinical
practice is having effective surveillance tools, and ultra-
sound’s effectiveness is variable with some studies
reporting a sensitivity as low as 32% in clinical practice.7
Inadequate ultrasound sensitivity is the most common
reason for late stage tumour detection in patients fol-
lowed in tertiary-care centres.8 This gap between ultra-
sound’s efficacy and effectiveness can be related to
several factors including differences in imaging protocols,
differences in patient populations, and the operator
dependent nature of ultrasound.9 Enthusiasm for alter-
nate radiological modalities, such as computerised
tomography and magnetic resonance imaging, in all
patients with cirrhosis is hampered by concerns regard-
ing radiation exposure and cost.10, 11
Characterising reasons for ultrasound failure and iden-
tifying patients in whom ultrasound is inadequate for
evaluation of HCC is important for informing interven-
tions to improve surveillance effectiveness. Therefore, the
aim of our study was to evaluate ultrasound quality and
identify clinical predictors of inadequate ultrasound qual-
ity among a large cohort of patients with cirrhosis
undergoing HCC surveillance.
METHODS
Study setting and patient population
We conducted a retrospective cohort study among 941
patients who underwent at least one abdominal ultra-
sound for a cirrhosis-related indication at Parkland
Health and Hospital System between 1 April 2015 and
31 October 2015. Parkland is the integrated safety-net
health system of Dallas County comprised of twelve pri-
mary care clinics, a Hepatology out-patient clinic, a mul-
tidisciplinary HCC clinic, and a tertiary hospital – all
sharing one electronic medical record system.12 Parkland
currently provides out-patient and in-patient care for
over 2000 patients with cirrhosis in Dallas. Parkland
utilises 18 in-patient and out-patient ultrasound scanners
and performs >3500 ultrasound examinations per month.
Ultrasounds are performed by one of 29 ultrasound tech-
nologists using a standard protocol and interpreted by
one of 26 subspecialty radiologists. All examinations
were performed on an iU22 or Epiq7 ultrasound system
(Philips Healthcare, Cleveland, OH, USA), utilising a
C5-1 or C9-2 curvilinear probe for deep imaging, and an
L12-5 or L12-3 linear probe for superficial imaging. The
liver ultrasound protocol involves sequential longitudinal
and transverse imaging through the left and right hepatic
lobes; high-resolution imaging of the hepatic capsule;
Doppler interrogation of the main portal vein; evaluation
of the gall-bladder and biliary system; measurement of
spleen length and volume; and assessment for ascites.
Patients were identified by an electronic search of all
patients who completed abdominal ultrasound exams.
One author (O.S.) adjudicated cases to confirm they met
diagnostic criteria for cirrhosis, including stage 4 fibrosis
on liver biopsy, any non-invasive marker of fibrosis sug-
gesting cirrhosis, or a cirrhotic-appearing liver on
abdominal imaging. This study was approved by the
Institutional Review Board of UT Southwestern Medical
Center and conducted in compliance with Health Infor-
mation and Privacy Accountability Act.
Data collection
Patient demographics, clinical history, and laboratory
data were obtained through review of computerised med-
ical records using a standardised collection form. Patient
age, gender, race, ethnicity and body mass index (BMI)
at the time of the ultrasound were recorded. BMI was
categorised using the International classification schema
as: normal (BMI <25), overweight (BMI 25–29.99), obese
class I (BMI 30–34.99), obese class II (BMI 35–39.99),
and morbid obesity (BMI ≥40). Patients were classified
according to aetiology of liver disease using laboratory
data and clinical notes as follows: hepatitis C virus (posi-
tive HCV antibody or viral load), hepatitis B virus (posi-
tive HBsAg or viral load), alcohol-related liver disease
(as determined by clinic provider), non-alcoholic steato-
hepatitis (presence of metabolic syndrome in the absence
of other causes of chronic liver disease or as determined
by clinic provider), and other. Data regarding presence
of decompensation (ascites or hepatic encephalopathy)
were abstracted from clinical notes and classified as
none, mild or controlled, and severe or uncontrolled.
Laboratory data of interest included platelet count, crea-
tinine, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), bilirubin, albumin, international
170 Aliment Pharmacol Ther 2017; 45: 169–177
ª 2016 John Wiley & Sons Ltd
O. Simmons et al.
normalised ratio (INR) and alpha fetoprotein (AFP). All
laboratory data were within 6 months of ultrasound
examination. For patients with multiple laboratory
results, we used those values closest to the ultrasound
date.
We recorded the location (in-patient vs. out-patient),
intent (surveillance vs. diagnostic exam), and quality for
each ultrasound exam. For patients with more than one
ultrasound exam, we selected the first ultrasound during
the study period. Intent of ultrasound imaging was
determined through review of ultrasound reports and
orders. Indications including ‘surveillance’, ‘screening’,
‘rule out HCC’ and ‘cirrhosis’ were classified as surveil-
lance indications. Ultrasound exams performed for diag-
nostic reasons, for example, abdominal pain or elevated
liver enzymes, were classified as nonsurveillance exams.
One of three fellowship-trained abdominal radiolo-
gists, experienced in ultrasound (D.F., T.Y. or T.B.), who
were blinded to the radiology clinical report and patient
characteristics, reviewed an equal number of ultrasound
exams. Ultrasound quality was categorised as definitely
adequate, likely adequate, likely inadequate or definitely
inadequate according to the radiologist’s confidence in
visualisation of the entire liver and ability to exclude any
Table 1 | Patient characteristics
Characteristic
Adequate ultrasound
quality (n = 750)
Inadequate ultrasound
quality (n = 191) P-value
Age (years) 56.5  9.8 56.9  10.2 0.60
Gender (% male) 466 (62.1%) 133 (70.0%) 0.04
Race/ethnicity
Non-Hispanic Caucasian 192 (25.6%) 50 (26.3%) 0.15
Black 260 (34.7%) 39 (20.5%)
Hispanic 261 (34.8%) 96 (50.5%)
Other/unknown 37 (4.9%) 5 (2.7%)
BMI
Normal (BMI <25) 243 (32.5%) 25 (13.2%) <0.001
Overweight (BMI 25–29.99) 242 (32.4%) 53 (28.0%)
Obesity class II (BMI 30–34.99) 152 (20.3%) 45 (23.8%)
Obesity class II (BMI 35–39.99) 60 (8.0%) 33 (17.5%)
Morbid obesity (BMI ≥40) 51 (6.8%) 33 (17.5%)
Aetiology of liver disease
Hepatitis C 383 (51.15%) 64 (33.7%) 0.08
Hepatitis B 44 (5.9%) 8 (4.2%)
Alcohol-related 116 (15.5%) 53 (27.9%)
Non-alcoholic steatohepatitis 72 (9.6%) 38 (20.0%)
Cryptogenic 99 (13.2%) 23 (12.0%)
Other* 36 (4.8%) 4 (2.1%)
Child Pugh class
Child Pugh A 541 (72.1%) 104 (54.5%) <0.001
Child Pugh B 167 (22.3%) 60 (31.4%)
Child Pugh C 42 (5.6%) 27 (14.1%)
Presence of hepatic encephalopathy (%) 113 (15.1%) 46 (24.2%) 0.003
Presence of ascites (%) 211 (28.1%) 81 (42.6%) <0.001
In-patient status (%) 152 (20.3%) 54 (28.3%) 0.02
Platelet count (*109/L) 158.2  82.7 138.5  89.1 0.004
Creatinine (mg/dL) 1.1  1.2 0.9  0.5 0.05
AST (U/L) 63.7  58.4 60.5  52.4 0.54
ALT (U/L) 56.1  73.6 44.9  36.8 0.04
Albumin (g/dL) 3.7  0.7 3.5  0.8 <0.001
Bilirubin (mg/dL) 1.1  1.5 1.2  3.2 <0.001
INR 1.2  0.4 1.3  0.5 0.01
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalised ratio.
* Other aetiology category includes 22 patients with autoimmune hepatitis, seven primary biliary cirrhosis, five cardiac cirrhosis,
three primary sclerosing cholangitis, one hemochromatosis, one sarcoidosis, and one parasitic infection.
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liver lesions including HCC. All three radiologists
reviewed the first 50 exams and quality scores were
determined by consensus to calibrate quality assessment,
after which time there was felt to be sufficiently high
inter-rater reliability for independent review of subse-
quent exams. The remaining ultrasounds were then
reviewed by one of the three radiologists. Quality assess-
ment was based on an overall impression of overall exam
quality based on combination of anatomical coverage
(less than 2/3 of liver visualised), visual clarity of the
liver parenchyma including heterogeneity and nodularity,
depth of penetration and any other exam limitations
such as obstruction from ribs, lungs or bowel gas. Given
the lack of accepted quality benchmarks for ultrasound
exam adequacy, these criteria were developed as the min-
imum needed for an ultrasound exam to be regarded as
adequate for HCC surveillance.
Statistical analysis
Our primary outcome of interest was adequacy of the
ultrasound exam for exclusion of liver lesions including
HCC; this was defined as a composite outcome of defi-
nite or likely adequate. Demographics and clinical fea-
tures were compared between patients with adequate and
inadequate ultrasound quality using the Student’s t-test
and chi square test for continuous and categorical vari-
ables, respectively. We used univariate and multivariable
logistic regression analyses to identify patient-factors
associated with adequate vs. inadequate ultrasound qual-
ity. Multivariable analysis included variables of a priori
clinical importance (e.g. obesity and Child Pugh class)
and predictor variables with P < 0.05 in univariate




Baseline characteristics of the 941 eligible patients are
detailed in Table 1. Mean age was 56.5  9.9 years and
63.7% were men. The cohort was racially/ethnically
diverse with 25.7% non-Hispanic Caucasian, 31.8%
Black, and 38.0% Hispanic. Over 39.1% were obese with
a BMI >30, and 9.0% were classified as having morbid
obesity with BMI >40. The most common aetiologies of
cirrhosis were HCV infection (47.6%), alcohol-induced
(18.0%), and NASH (11.7%). Most patients had compen-
sated cirrhosis, with 68.5% having Child Pugh A cirrho-
sis, 24.1% Child Pugh B cirrhosis, and 7.3% Child Pugh
C cirrhosis. Ascites was present in 31.1% of patients, and
16.9% had hepatic encephalopathy. Most ultrasounds
were done as an out-patient, although 21.9% of exams
were performed while an in-patient.
Ultrasounds were determined to be inadequate in 191
(20.3%) of cases – 134 definitely inadequate and 57 likely
inadequate (Figure 1). The most common reasons for inade-
quate ultrasound exams were rib shadowing and inadequate
beam penetration allowing visualisation of less than two-
thirds of the hepatic parenchyma. There were 26 patients
with poor beam penetration, 33 with rib shadowing, and 82
patients with both quality issues. Liver heterogeneity and
bowel gas were uncommon reasons for inadequate ultra-
sounds, reported in only 20 and eight patients respectively.
Illustrative examples are shown in Figure 2.
0
Definitely adequate Likely adequate
Ultra sound quality evaluation






















Figure 1 | Quality of ultrasound exams for exclusion of liver masses. Among 941 patients, ultrasounds were
inadequate in 191 (20.3%) of cases – 134 definitely inadequate and 57 likely inadequate.
172 Aliment Pharmacol Ther 2017; 45: 169–177
ª 2016 John Wiley & Sons Ltd
O. Simmons et al.
In univariate analyses, inadequate ultrasound quality
was significantly associated with male gender, Child
Pugh B or C cirrhosis, BMI category, alcohol or NASH
aetiology of liver disease, elevated ALT level, and
in-patient status (Table 2). Although the individual com-
ponents of Child Pugh score were associated with ultra-
sound quality, they were not included in multivariable
analysis given clinical collinearity. In multivariable analy-
sis, inadequate ultrasound quality was directly associated
with male gender, increasing BMI category, in-patient
status, Child Pugh B or C cirrhosis, alcohol-related cir-
rhosis and NASH-related cirrhosis. Ultrasounds were
inadequate in 16.1% of patients with Child Pugh A cir-
rhosis, 26.4% of those with Child Pugh B cirrhosis, and
39.1% of patients with Child Pugh C cirrhosis. Similarly,
inadequate quality was observed in 9.3% of normal-
weight patients, 18.0% of overweight patients, 22.8% of
patients with obesity class I, 35.5% of patients with obe-
sity class II, and 39.3% of patients with morbid obesity.
Ultrasound exams were inadequate in 31.4% of patients





Figure 2 | Illustrative examples of adequate and inadequate ultrasound quality. (a) Adequate-quality exam: Although
diffusely heterogeneous, liver parenchyma is clearly visualised and focal liver lesions were ruled out with high
confidence. (b) Inadequate-quality exam: Right hepatic dome could not be visualised due to extensive rib shadowing.
(c) Inadequate-quality exam: Posterior half of the liver could not be visualised due to severe parenchymal fatty liver
disease. (d) Inadequate-quality exam: Liver parenchyma is poorly visualised throughout due to morbid obesity and
thick subcutaneous/visceral fat, in addition to probable severe underlying parenchymal disease.
Table 2 | Factors associated with inadequate ultrasound quality (N = 941)
Characteristic
Univariate analysis Multivariable analysis
OR 95% CI OR 95% CI
Male gender 1.42 1.01–2.01 1.68 1.14–2.48
Child Pugh B or C cirrhosis 2.17 1.56–3.00 1.93 1.32–2.81
BMI category
Normal (BMI <25) Ref Ref Ref Ref
Overweight (BMI 25–29.99) 2.12 1.28–3.54 2.29 1.35–3.88
Obesity class II (BMI 30–34.99) 2.88 1.70–4.89 2.95 1.67–5.20
Obesity class II (BMI 35–39.99) 5.35 2.96–9.66 6.37 3.35–12.12
Morbid obesity (BMI ≥40) 6.29 3.45–11.47 8.22 4.30–15.73
Aetiology of liver disease
Hepatitis C Ref Ref Ref Ref
Hepatitis B 1.09 0.49–2.42 1.87 0.79–4.39
Alcohol-related 2.73 1.80–4.16 2.11 1.33–3.37
Non-alcoholic steatohepatitis 3.16 1.97–5.07 2.87 1.71–4.80
Other 0.66 0.23–1.93 0.67 0.22–2.04
ALT >40 U/L 0.70 0.50–0.97 0.93 0.64–1.34
In-patient status 1.55 1.08–2.23 1.55 1.01–2.37
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with alcohol-related cirrhosis and 34.6% of patients with
NASH-related cirrhosis, compared to only 15.0% of
patients with other aetiologies of cirrhosis. Among the
55 patients with BMI >30, alcohol or NASH aetiology,
and Child Pugh B or C cirrhosis, 25 (45.5%) had ultra-
sounds of inadequate quality. In contrast, ultrasound was
inadequate in only 4.4% of patients without any of these
characteristics, that is, normal-weight patients with Child
Pugh A cirrhosis due to aetiologies other than alcohol or
NASH.
There were 625 patients with definite signs of cirrhosis
– 98 by biopsy and 527 by imaging showing a cirrhotic
appearing liver with signs of portal hypertension. Among
this subset, ultrasound was determined to be inadequate
in 141 (22.6%) of cases – 98 definitely inadequate and
43 likely inadequate. As above, the most common rea-
sons for inadequate ultrasound exams were rib shadow-
ing and inadequate beam penetration allowing
visualisation of less than two-thirds of the hepatic par-
enchyma. Although parenchyma heterogeneity was
reported more often among the subset of patients with
definite cirrhosis, this still accounted for less than 13%
of patients. Factors associated with inadequate ultra-
sound in multivariable analysis were the same as the pri-
mary cohort (Table 3). In a sensitivity analysis excluding
patients with Child C cirrhosis, 121 (20.8%) patients had
inadequate quality ultrasound exams. Male gender,
increasing BMI category, in-patient status, and Child
Pugh B cirrhosis continued to be associated with inade-
quate ultrasound quality; however, alcohol- and NASH-
related cirrhosis were no longer statistically significant
on multivariable analysis (data not shown).
DISCUSSION
Current guidelines from the American Association for
the Study of Liver Diseases (AASLD) and European
Association for the Study of the Liver (EASL) recom-
mend ultrasound alone for HCC surveillance, but there
have been few studies characterising ultrasound quality
and defining populations in whom ultrasound is prone
to failure.1, 13 We found that 20% of all ultrasound
exams in our cohort of patients with cirrhosis were cate-
gorised as inadequate quality for HCC surveillance. The
most common reasons for inadequate quality were rib
shadowing and inadequate ultrasound beam penetration.
Inadequate ultrasound quality was significantly associ-
ated with in-patient status, male gender, obesity, Child
Pugh B or C cirrhosis, and alcohol or NASH aetiology
of liver disease.
It is becoming increasingly evident that ultrasound
limitations contribute to deficiencies in HCC surveillance
effectiveness in clinical practice. A prior study from Italy
demonstrated ultrasound failed to detect 30% of HCC at
an early stage, while another study from Canada
reported ultrasound failure in approximately 25% of
cases.14, 15 The authors postulated this was due to a
Table 3 | Factors associated with inadequate ultrasound quality in subset of patients with definite features of cirrhosis
on imaging (N = 625)
Characteristic
Univariate analysis Multivariable analysis
OR 95% CI OR 95% CI
Male gender 1.51 0.99–2.29 1.72 1.07–2.77
Child Pugh B or C cirrhosis 1.99 1.36–2.90 1.65 1.06–2.57
BMI category
Normal (BMI <25) Ref Ref Ref Ref
Overweight (BMI 25–29.99) 2.15 1.16–3.99 2.60 1.36–4.97
Obesity class II (BMI 30–34.99) 2.79 1.46–5.30 3.47 1.74–6.94
Obesity class II (BMI 35–39.99) 4.22 2.04–8.74 5.59 2.54–12.30
Morbid obesity (BMI ≥40) 6.39 3.07–13.32 8.86 4.02–19.51
Aetiology of liver disease
Hepatitis C Ref Ref Ref Ref
Hepatitis B 1.23 0.44–3.45 2.02 0.67–6.10
Alcohol-related 2.28 1.43–3.61 1.84 1.09–3.09
Non-alcoholic steatohepatitis 2.47 1.37–4.44 2.48 1.30–4.75
Other 0.64 0.22–1.89 0.73 0.24–2.28
ALT >40 U/L 0.68 0.46–1.01 0.92 0.59–1.43
In-patient status 2.14 1.40–3.27 2.11 1.27–3.51
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combination of aggressive tumour biology and surveil-
lance ultrasound’s imperfect sensitivity; however, they
could not determine the relative contribution of each
factor. Our study helps further evaluate this issue, find-
ing ultrasound quality may be inadequate, predisposing
to surveillance failure in approximately 20% of patients.
To the best of our knowledge, our study is the first to
demonstrate that surveillance ultrasound exam quality is
impaired in obese patients and those with alcohol or
NASH-related cirrhosis. The association between BMI
and inadequate ultrasound quality is likely mediated by
attenuation of the ultrasound beam by subcutaneous fat,
impairing the ability to obtain high-quality images of the
entire liver.16 Although some techniques, such as reposi-
tioning, increased pressure on the transducer, or use of a
lower frequency transducer, can overcome some of these
effects, it is unclear how often this is done in high-
volume clinical practices. Similarly, alcohol- and NASH-
related cirrhosis are both steatosis-mediated conditions, a
tissue property that can exacerbate attenuation of the
ultrasound pulse and impair visualisation of deep struc-
tures, including liver masses.17 Unlike subcutaneous fat,
there are fewer well-described techniques to overcome
this issue. Although the association between ultrasound
quality and alcohol- or NASH-related cirrhosis was no
longer significant on sensitivity analysis when excluding
Child Pugh C cirrhosis, this may have been due to
limited sample size.
We also found inadequate ultrasound quality was
associated with Child Pugh B or C cirrhosis and male
gender – two factors previously reported to be associ-
ated with surveillance ultrasound failure.14 Child Pugh
B or C cirrhosis may intuitively pre-dispose to inade-
quate ultrasound quality given increased liver nodular-
ity and parenchymal heterogeneity, impairing the
ability of radiologists to distinguish focal liver lesions,
including HCC. A severely shrunken liver in Child
Pugh B or C cirrhosis is also more difficult to visu-
alise as most of the liver is retracted under the rib
cage, even at deep-inspiration. However, the reason for
the association between male gender and inadequate
ultrasound quality is less clear. Del Poggio and col-
leagues postulated this association may be driven by
higher rates of obesity and steatosis14; however, male
gender continued to be associated with inadequate
ultrasound quality after adjustment for these factors in
our study. We found male patients were significantly
more likely to have rib shadowing (62.4% vs. 43.9%,
P = 0.02) in exploratory post hoc analyses, but this
association requires validation in future studies.
Although several factors associated with ultrasound
adequacy were immutable, in-patient status was signifi-
cantly associated with worse ultrasound quality. This
association may be due to differences in ultrasound
operator experience, patient difficulty with exam cooper-
ation while acutely ill, or clinical deterioration (e.g.
increased ascites) that might hamper exam quality.
Although it might be convenient for patients to have
HCC surveillance performed while being seen as an in-
patient, our study highlights that this approach might
hinder obtaining a high-quality exam and limit surveil-
lance effectiveness in the long term.
The issue of compromised ultrasound quality and
surveillance failure may become more problematic as the
epidemiology of HCC shifts from primarily HCV-
mediated to NASH-mediated, highlighting the need for
improvements in ultrasound image acquisition and/or
evaluation of alternative surveillance modalities.18, 19 Use
of cross-sectional modalities such as CT or MRI may
increase sensitivity for HCC; however, there are no data
evaluating their performance as a surveillance strategy.
Furthermore, the increased cost and adverse effect pro-
file, such as radiation exposure, limit their use as a pri-
mary surveillance modality in all-comer patients with
cirrhosis. Studies are needed to determine if this strategy
could be cost effective if limited to a subset of patients
who are both high risk for HCC and prone to ultra-
sound failure.20 Despite a lack of alternative imaging
modalities, there is hope that HCC biomarkers can
increase early tumour detection rates in clinical practice.
Using AFP, the best studied biomarker to date, in com-
bination with surveillance ultrasound may increase sensi-
tivity for early HCC in clinical practice.7, 21 Adding AFP
may be particularly beneficial in patients with alcohol-
or NASH-related cirrhosis; not only is ultrasound prone
to failure in these patients but AFP also has higher speci-
ficity and overall accuracy for early HCC detection as
compared to its performance in patients with HCV-
related cirrhosis.22 Novel biomarkers are also being
explored through multi-centre efforts such as the Early
Detection Research Network (EDRN).23
Our study had a few limitations. Our study was con-
ducted at a single centre with a high volume of cirrhotic
patients and surveillance ultrasound exams using fellow-
ship-trained abdominal radiologists, and our results may
not be generalised to all practice settings, particularly
given the operator dependent nature of ultrasound. Sec-
ond, our study had a small number of HBV patients so
interpretability of results in this subgroup is more lim-
ited. Third, we cannot exclude possible unmeasured
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confounders or measurement bias given the retrospective
nature of our study. For example, we used BMI as a
measure of obesity given lack of data regarding factors
such as truncal obesity or degree of visceral fat. Fourth,
ultrasound quality was determined using static images
reviewed by a radiologist, which may not be representa-
tive of the entire ultrasound examination as performed
by the technologist. However, we feel this is reflective of
how ultrasound exams are typically performed in the
USA and interpreted so our results should reflect ultra-
sound quality in clinical practice. Finally, our outcome
was a subjective assessment of ultrasound quality and
adequacy for HCC surveillance; although inadequate
ultrasound quality would intuitively predispose to HCC
surveillance failure, further studies are needed to firmly
establish this association.
In summary, we found that one in 5 ultrasound exams
in our cohort of patients with cirrhosis were of inade-
quate quality for HCC surveillance. The most common
reasons for inadequate quality were rib shadowing and
inadequate ultrasound beam penetration. Obesity, Child
Pugh B or C cirrhosis, and alcohol or NASH-related cir-
rhosis are associated with inadequate ultrasound quality,
with these patients having inadequate exams in over
one-third of cases. Alternative surveillance strategies may
be needed, particularly for subgroups prone to surveil-
lance ultrasound failure.
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